EANS-News: Epigenomics AG to Suggest Reduction of Share Capital and 5:1 Reverse Stock Split at Upcoming AGM

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Annual & Special Corporate Meetings/Company Information/molecular
diagnostics

Berlin, Germany, May 18, 2011 (euro adhoc) - Epigenomics AG
(Frankfurt Prime Standard: ECX), the cancer molecular diagnostics
company, today issued invitations to its Annual General Shareholders´
Meeting scheduled for June 28, 2011.

Among other items, the agenda includes a decision proposal by the
Executive Board and the Supervisory Board to reduce the Company´s
share capital according to Sections 229 et seqq. of the German Stock
Corporation Act (AktG) concomitant with a 5:1 reverse stock split.
The share capital would be reduced from the current total of EUR
44,092,085.00 to EUR 8,818,417.00, allocated to 8,818,417 shares
outstanding. The difference of EUR 35,273,668.00 would be credited to
the capital reserve, leaving shareholder´s equity and balance sheet
total unchanged.

The reduction in share capital and the consolidation of the shares
would serve in the full amount to offset depreciation and cover
other losses.

With the release of its financial statements for 2010 on April 7,
2011, Epigenomics indicated that within the second half of 2011 its
accrued losses according to German GAP may surpass half of the
Company´s share capital. According to Sec. 92 Para. 1 of the AktG,
this would trigger an immediate convocation of an Extraordinary
Shareholders´ Meeting.

By the suggested reduction of the share capital an Extraordinary
Shareholders´ Meeting could be avoided. Furthermore, the company
expects that the measure will improve the key indicators per share,
which may lead to an improved rating of Epigenomics´ shares. This
would increase flexibility in potential future financial or strategic
capital markets transactions. At the upcoming Annual General
Shareholders´ Meeting Epigenomics´ Executive Board will report on the
commercial and financial status of the Company and is available for
questions by its shareholders.

On March 31, 2011, Epigenomics´ liquid assets amounted to EUR 23.5
million.

Further details on the upcoming Annual General Shareholder`s Meeting
2011 are available at http://www.epigenomics.com/en/news-investors/in
vestors/annual-general-shareholder-meeting.html

- Ends -

Contact Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 368
pr@epigenomics.com
www.epigenomics.com

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company´s products enable doctors to diagnose cancer
earlier and more accurately, leading to improved outcomes for
patients. Epigenomics´ lead product, Epi proColon®, is a blood-based
test for the early detection of colorectal cancer, which is currently
marketed in Europe and is in development for the U.S.A. The Company´s
technology and products have been validated through multiple
partnerships with leading global diagnostic companies including
Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an
international company with operations in Europe and the U.S.A.

Epigenomics legal disclaimers. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: www.epigenomics.com
sector: Biotechnology
ISIN: DE000A0BVT96, DE000A0XFWF2
indexes: Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, München
language: English

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel: +49 30 24345 368
achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade